Practical impact of COVID-19 on CHR patients, individualizing DOR treatment & more
May 2020 CHR VOICE Digest
During April, the coronavirus and COVID-19, in all spheres of life, continued to dominate the nation’s existence. That, of course, also applies here at CHR. We are, however, very pleased to report that so-far only one of our staff members has contracted the virus. She has been home for over a month and is recovering well. CHR has continued to function “normally,” if anything can still be considered to function “normally” these days. In practical terms, CHR, in contrast to most other IVF centers in New York City and the country, never shut down. We have curtailed non-urgent clinical activities but continued to offer all treatments our patients and CHR concurred were urgent, relying on the telemedicine capabilities we've developed over the years for our international and US long-distance patients.
Dr. Gleicher's live webinar on DHEA was attended by over 4,000 viewers.
The COVID-19 pandemic, unsurprisingly, also still dominates this issue of the VOICE. But we, in addition, also are discussing some clinical issues that attracted enormous attention during a worldwide virtual professional infertility conference in April. The conference was expected to attract notmore than 1,000 virtual attendees; yet, it ended up with over 14,000 fertility specialists joining online. A lecture on the clinical utilization of dehydroepiandrosterone (DHEA) by CHR’s Medical Director and Chief Scientist, Norbert Gleicher, MD, attracted the largest number of immediate downloads at the conference (over 4,000, and a few thousand additional ones over the following days). Because of this unexpected and overwhelming interest in the subject of low functional ovarian reserve (LFOR),we decided to initiate with this issue of the VOICE a detailed series of articles on how to individualize treatments in women with LFOR. Here we present the first installment.
In this issue of the CHR VOICE, we cover:
- Practical consequences of COVID-19 pandemic on CHR's fertility patients
- The essence of the COVID-19 crisis
- How to individualize fertility treatment for women with low functional ovarian reserve (#1 in the DOR/LFOR series)
Norbert Gleicher, MD, leads CHR’s clinical and research efforts as Medical Director and Chief Scientist. A world-renowned specialist in reproductive endocrinology, Dr. Gleicher has published hundreds of peer-reviewed papers and lectured globally while keeping an active clinical career focused on ovarian aging, immunological issues and other difficult cases of infertility.
We have helped women bring over 17,800 babies into the world.Discover your treatment options
- Breaking News in ScienceLetter to President Biden and Secretary Designate of HHS, Xavier Becerra In a published letter (Santoro et al Reprod Sciences 2021; https:/doi.org/10.1007/s43032-021-00491-9), a
- More On COVID-19DOES THE BRITISH STRAIN B.1.1.7 INCREASE MORTALITY OVER D614G? A just published study by British investigators claims that not only infectivity of the
- Mild Ovarian StimulationTwo prominent voices in the fertility field known as longstanding supporters of mild ovarian stimulation were at it once again (Nargund and Fauser, Reprod Biomed Online 2020;41:569-571) when
- Brief Case Studies in Clinical InfertilityIs there a place for DHEA and CoQ10 in women undergoing “planned” egg-freezing? At CHR, women undergoing egg-freeing cycles undergo a very